thrombocytopenia reported possible benefit for arm) of HIV-positive patients with severe the restoration and maintenance of platelet thrombocytopenia reported possible benefit for count for the duration of the haemorrhagic the restoration and maintenance of platelet disorder (Biotext 2004). count for the duration of the haemorrhagic disorder (Biotext 2004). An international consensus statement from January 2010 (Provan et al 2010) reported on An international consensus statement from new data and provided consensus-based January 2010 (Provan et al 2010) reported on recommendations relating to diagnosis and new data and provided consensus-based treatment of ITP in adults, in children, and during recommendations relating to diagnosis and pregnancy. This statement concluded that few treatment of ITP in adults, in children, and RCTs have been conducted and that multi-centre, during pregnancy. This statement concluded prospective RCTs are required. that few randomised controlled trials (RCTs) have been conducted and that multi-centre, prospective RCTs are required. A 2005 review on the management of Evans syndrome, based on Massachusetts Hospital data and a literature review, showed a transient response in all patients unless IVIg was given every three weeks (Norton and Roberts 2006). The review concluded that the data supported a role for IVIg in first-line therapy. It was not clear whether it was important for steroids to be given at the same time, although this is common practice. A total dose of 2 g/kg in
thrombocytopenia reported possible benefit for the restoration and maintenance of platelet count for the duration of the haemorrhagic disorder (Biotext 2004). An international consensus statement from January 2010 (Provan et al 2010) reported on new data and provided consensus-based recommendations relating to diagnosis and treatment of ITP in adults, in children, and during pregnancy. This statement concluded that few RCTs have been conducted and that multi-centre, prospective RCTs are required. arm) of HIV-positive patients with severe thrombocytopenia reported possible benefit for the restoration and maintenance of platelet count for the duration of the haemorrhagic disorder (Biotext 2004). An international consensus statement from January 2010 (Provan et al 2010) reported on new data and provided consensus-based recommendations relating to diagnosis and treatment of ITP in adults, in children, and during pregnancy. This statement concluded that few randomised controlled trials (RCTs) have been conducted and that multi-centre, prospective RCTs are required. A 2005 review on the management of Evans syndrome, based on Massachusetts Hospital data and a literature review, showed a transient response in all patients unless IVIg was given every three weeks (Norton and Roberts 2006). The review concluded that the data supported a role for IVIg in first-line therapy. It was not clear whether it was important for steroids to be given at the same time, although this is common practice. A total dose of 2 g/kg in
idiopathic-autoimmune-thrombocytopenic-purpura-itp-adult.DOCX